PMID- 10594561
OWN - NLM
STAT- MEDLINE
DCOM- 20000113
LR  - 20190513
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 118
IP  - 3
DP  - 1999 Dec
TI  - Elevated levels of beta-chemokines in bronchoalveolar lavage fluid (BALF) of 
      individuals infected with human T lymphotropic virus type-1 (HTLV-1).
PG  - 417-22
AB  - Pulmonary complications are known to develop in HTLV-1 carriers, including T 
      lymphocytic alveolitis, and increased IL-2 receptor alpha (CD25)-bearing T cells 
      have been found in BALF. Several chemokines may contribute to accumulation of T 
      lymphocytes in the lungs of HTLV-1 carriers. Here, we compared the distribution 
      of T lymphocyte subsets and beta-chemokines, such as macrophage inflammatory 
      peptide-1alpha (MIP-1alpha), regulated on activation normal T expressed and 
      secreted (RANTES), and macrophage chemoattractant protein-1 (MCP-1), in BALF and 
      peripheral blood between HTLV-1 carriers and non-infected healthy normal 
      subjects. Flow cytometric analysis with MoAbs to cell surface antigens was used 
      to identify T lymphocyte subsets in BALF samples from HTLV-1 carriers (n = 13) 
      and non-infected healthy controls (n = 10). The levels of different 
      beta-chemokines were estimated by ELISA. High percentages of CD3+ cells, CD3 
      expressing HLA-DR antigen and CD3+CD25+ cells were detected in BALF of HTLV-1 
      carriers compared with non-infected controls. The concentration of MIP-1alpha in 
      BALF of patients was significantly higher than in non-infected healthy controls 
      and correlated well with the percentage of CD3+CD25+ cells. The level of RANTES 
      in BALF was also significantly high in HTLV-1 carriers, but did not correlate 
      with the percentage of CD3+CD25+ cells. On the other hand, the level of MCP-1 in 
      BALF of HTLV-1 carriers was not different from that of controls. Our results 
      suggest a possible interaction between activated T cells bearing CD25 and 
      beta-chemokines, especially MIP-1alpha, which may contribute to the pulmonary 
      involvement in HTLV-1 carriers.
FAU - Seki, M
AU  - Seki M
AD  - Second Department of Internal Medicine, Nagasaki University School of Medicine, 
      Nagasaki, Japan.
FAU - Kadota, J I
AU  - Kadota JI
FAU - Higashiyama, Y
AU  - Higashiyama Y
FAU - Iida, K
AU  - Iida K
FAU - Iwashita, T
AU  - Iwashita T
FAU - Sasaki, E
AU  - Sasaki E
FAU - Maesaki, S
AU  - Maesaki S
FAU - Tomono, K
AU  - Tomono K
FAU - Kohno, S
AU  - Kohno S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (CD3 Complex)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL3)
RN  - 0 (Chemokine CCL4)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Chemokines, CC)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Macrophage Inflammatory Proteins)
RN  - 0 (Receptors, Interleukin-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bronchoalveolar Lavage Fluid/*chemistry/cytology
MH  - CD3 Complex/metabolism
MH  - Cell Count
MH  - Chemokine CCL2/analysis
MH  - Chemokine CCL3
MH  - Chemokine CCL4
MH  - Chemokine CCL5/analysis
MH  - Chemokines, CC/*analysis
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Flow Cytometry
MH  - HLA-DR Antigens/metabolism
MH  - HTLV-I Infections/*immunology
MH  - Humans
MH  - Lung Diseases/*immunology
MH  - Lymphocytosis/immunology/metabolism/pathology
MH  - Macrophage Inflammatory Proteins/analysis
MH  - Male
MH  - Middle Aged
MH  - Receptors, Interleukin-2/metabolism
MH  - T-Lymphocyte Subsets/cytology/immunology/metabolism
PMC - PMC1905436
EDAT- 1999/12/14 00:00
MHDA- 1999/12/14 00:01
PMCR- 2000/12/01
CRDT- 1999/12/14 00:00
PHST- 1999/12/14 00:00 [pubmed]
PHST- 1999/12/14 00:01 [medline]
PHST- 1999/12/14 00:00 [entrez]
PHST- 2000/12/01 00:00 [pmc-release]
AID - cei1093 [pii]
AID - 10.1046/j.1365-2249.1999.01093.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 1999 Dec;118(3):417-22. doi: 10.1046/j.1365-2249.1999.01093.x.